 |
41 Diseases |  |
16 Trials |
|
16 Trials |  |
501 News |  |
| «12345678» |
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Aug 6, 2018
P4, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2019 --> Sep 2020
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment closed, Combination therapy: ATLANT: Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (clinicaltrials.gov) - Jul 31, 2018
P2, N=40, Active, not recruiting, Sponsor: Ipsen
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2019 --> Sep 2020 Recruiting --> Active, not recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion, HEOR: ACRO QLQ: Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel (clinicaltrials.gov) - Jul 30, 2018
P=N/A, N=152, Completed, Sponsor: Ipsen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, Enrollment change, Metastases: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Jul 30, 2018
P=N/A, N=22, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed Recruiting --> Completed | N=100 --> 22
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial, HEOR: OPERA: Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel (clinicaltrials.gov) - Jul 16, 2018
P=N/A, N=115, Recruiting, Sponsor: Ipsen
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, HEOR: OPERA: Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel (clinicaltrials.gov) - Jul 16, 2018
P=N/A, N=115, Recruiting, Sponsor: Ipsen
Recruiting --> Completed | N=100 --> 22 Not yet recruiting --> Recruiting
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment closed, Metastases: Community-based Neuroendocrine Tumor (NET) Research Study (clinicaltrials.gov) - Jul 13, 2018
P=N/A, N=100, Active, not recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Observational data, Journal: A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. (Pubmed Central) - Jun 27, 2018
P=N/A
LAN was generally well tolerated with no new or unexpected safety signals reported during the observation period. clinicaltrials.gov Clinical Trial Identifier: NCT00686348.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, P3 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY. (Pubmed Central) - May 26, 2018
clinicaltrials.gov Clinical Trial Identifier: NCT00686348. Improvement in CS symptoms occurred with lanreotide treatment, regardless of prior octreotide use.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Enrollment closed, Enrollment change, Metastases: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (clinicaltrials.gov) - Apr 19, 2018
P2, N=6, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Improvement in CS symptoms occurred with lanreotide treatment, regardless of prior octreotide use. Recruiting --> Active, not recruiting | N=25 --> 6
- ||||||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion: PAOLA: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (clinicaltrials.gov) - Apr 6, 2018
P3, N=198, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=25 --> 6 Active, not recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, Trial completion date, Trial primary completion date, HEOR, Combination therapy: QoL in IMBO: Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (clinicaltrials.gov) - Feb 27, 2018
P2, N=43, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 | Trial primary completion date: Jan 2018 --> Jan 2018
- |||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: IMIO: Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (clinicaltrials.gov) - Jan 30, 2018
P2, N=52, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 | Trial primary completion date: Jan 2018 --> Jan 2018 Active, not recruiting --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date, Combination therapy: ATLANT: Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (clinicaltrials.gov) - Jan 30, 2018
P2, N=40, Recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Trial primary completion date: Oct 2018 --> Mar 2019
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date, Metastases: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Jan 30, 2018
P=N/A, N=100, Recruiting, Sponsor: Ipsen
Trial primary completion date: Oct 2018 --> Mar 2019 Trial primary completion date: Feb 2018 --> Jun 2018
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Enrollment change, HEOR, Combination therapy: QoL in IMBO: Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (clinicaltrials.gov) - Jan 30, 2018
P2, N=43, Active, not recruiting, Sponsor: Ipsen
Trial primary completion date: Feb 2018 --> Jun 2018 Recruiting --> Active, not recruiting | N=84 --> 43
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Trial initiation date, Metastases: Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET (clinicaltrials.gov) - Jan 17, 2018
P4, N=28, Recruiting, Sponsor: Samsung Medical Center
Recruiting --> Active, not recruiting | N=84 --> 43 Active, not recruiting --> Recruiting | Initiation date: Dec 2016 --> Jul 2017
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Dec 27, 2017
P2a, N=28, Completed, Sponsor: Ipsen
Active, not recruiting --> Recruiting | Initiation date: Dec 2016 --> Jul 2017 Active, not recruiting --> Completed
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed: IMIO: Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (clinicaltrials.gov) - Oct 30, 2017
P2, N=52, Active, not recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change, Trial termination, Combination therapy: PRELUDE: A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel (clinicaltrials.gov) - Oct 30, 2017
P=N/A, N=40, Terminated, Sponsor: Ipsen
Recruiting --> Active, not recruiting N=150 --> 40 | Recruiting --> Terminated; The study terminated prematurely due to insufficient recruitment.
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: SOMACROL: Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (clinicaltrials.gov) - Oct 30, 2017
P=N/A, N=115, Completed, Sponsor: Ipsen
N=150 --> 40 | Recruiting --> Terminated; The study terminated prematurely due to insufficient recruitment. Recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Phase classification, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Oct 20, 2017
P4, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed Phase classification: P2 --> P4
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, Circulating tumor cells, Tumor cell: CALM-NET: Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (clinicaltrials.gov) - Oct 2, 2017
P4, N=50, Completed, Sponsor: Ipsen
Phase classification: P2 --> P4 Active, not recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
New P4 trial, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Sep 26, 2017
P4, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
New P2 trial, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Sep 20, 2017
P2, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Trial primary completion date: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Aug 29, 2017
P2a, N=28, Active, not recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Nov 2017
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial termination, Surgery: A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. (clinicaltrials.gov) - Aug 18, 2017
P4, N=4, Terminated, Sponsor: John Wayne Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Nov 2017 Completed --> Terminated; Didn't enroll enough subjects
- | Keytruda (pembrolizumab) / Merck (MSD), Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment open: PLANET: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Jul 31, 2017
P1/2, N=26, Recruiting, Sponsor: Duke University
Completed --> Terminated; Didn't enroll enough subjects Not yet recruiting --> Recruiting
- |||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: SONNET: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (clinicaltrials.gov) - Jul 26, 2017
P2, N=57, Completed, Sponsor: Ipsen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change, Trial primary completion date: SOMACROL: Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (clinicaltrials.gov) - Jul 25, 2017
P=N/A, N=100, Recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed N=150 --> 100 | Trial primary completion date: Jun 2017 --> Sep 2017
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Trial completion: SOPRANo: Somatuline Predictive Factors in Acromegaly and NET (clinicaltrials.gov) - Jul 17, 2017
P=N/A, N=156, Completed, Sponsor: Ipsen
N=150 --> 100 | Trial primary completion date: Jun 2017 --> Sep 2017 Active, not recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial initiation date, Metastases: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (clinicaltrials.gov) - Jul 13, 2017
P2, N=25, Recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Initiation date: Jun 2017 --> Sep 2017
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. (Pubmed Central) - Jul 8, 2017
P3
Initiation date: Jun 2017 --> Sep 2017 Lanreotide depot/autogel is effective for the control of CS symptoms in patients (SSA-naïve or experienced) with NETs.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2 trial: A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula (clinicaltrials.gov) - Jun 1, 2017
P2, N=123, Not yet recruiting, Sponsor: University of Washington
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date, HEOR, Combination therapy: QoL in IMBO: Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (clinicaltrials.gov) - May 4, 2017
P2, N=84, Recruiting, Sponsor: Ipsen
Lanreotide depot/autogel is effective for the control of CS symptoms in patients (SSA-naïve or experienced) with NETs. Trial primary completion date: Mar 2017 --> Jan 2018
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P4 trial, Metastases: Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET (clinicaltrials.gov) - Mar 16, 2017
P4, N=28, Active, not recruiting, Sponsor: Samsung Medical Center
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (clinicaltrials.gov) - Mar 8, 2017
P2, N=25, Recruiting, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Mar 2017 --> Jan 2018 Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Mar 2017 | Trial primary completion date: Mar 2018 --> Mar 2019
- ||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: LANTERN: Efficacy and Safety of Lanreotide Autogel (clinicaltrials.gov) - Feb 27, 2017
P3, N=128, Completed, Sponsor: Ipsen
Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Mar 2017 | Trial primary completion date: Mar 2018 --> Mar 2019 Active, not recruiting --> Completed
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: SONNET: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (clinicaltrials.gov) - Feb 20, 2017
P2, N=57, Active, not recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Trial primary completion date: Oct 2018 --> Dec 2016
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Metastases: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Feb 19, 2017
P=N/A, N=100, Recruiting, Sponsor: Ipsen
Trial primary completion date: Oct 2018 --> Dec 2016 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
New P1/2 trial: PLANET: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Feb 6, 2017
P1/2, N=26, Not yet recruiting, Sponsor: Duke University
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Trial primary completion date: SOPRANo: Somatuline Predictive Factors in Acromegaly and NET (clinicaltrials.gov) - Jan 31, 2017
P=N/A, N=156, Active, not recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jul 2016
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: IMIO: Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (clinicaltrials.gov) - Jan 31, 2017
P2, N=50, Recruiting, Sponsor: Ipsen
Trial primary completion date: Dec 2016 --> Jul 2016 Trial primary completion date: Mar 2017 --> Oct 2017
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial, Metastases: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=100, Not yet recruiting, Sponsor: Ipsen
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date, Combination therapy: PRELUDE: A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=150, Recruiting, Sponsor: Ipsen
Trial primary completion date: Mar 2017 --> Oct 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion, Enrollment change, Trial primary completion date: Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma (clinicaltrials.gov) - Oct 6, 2016
P3, N=24, Completed, Sponsor: University Hospital, Ghent
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Completed | N=50 --> 24 | Trial primary completion date: Dec 2015 --> Dec 2014
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change, Trial termination, Trial primary completion date: ACRO-OPTIM: Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg (clinicaltrials.gov) - Oct 3, 2016
P=N/A, N=4, Terminated, Sponsor: Ipsen
Recruiting --> Completed | N=50 --> 24 | Trial primary completion date: Dec 2015 --> Dec 2014 N=183 --> 4 | Recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Jan 2016; The study was terminated early due to insufficient potential for recruitment.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Trial primary completion date, Circulating tumor cells, Tumor cell: CALM-NET: Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (clinicaltrials.gov) - Sep 2, 2016
P4, N=50, Active, not recruiting, Sponsor: Ipsen
N=183 --> 4 | Recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Jan 2016; The study was terminated early due to insufficient potential for recruitment. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jul 2017
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Enrollment change: SONNET: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (clinicaltrials.gov) - Sep 2, 2016
P2, N=56, Active, not recruiting, Sponsor: Ipsen
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jul 2017 Recruiting --> Active, not recruiting | N=40 --> 56
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
New P2 trial, Metastases: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (clinicaltrials.gov) - Aug 8, 2016
P2, N=25, Not yet recruiting, Sponsor: SCRI Development Innovations, LLC